SteelPeak Wealth LLC Takes Position in Tempus AI, Inc. $TEM

Key Points

• SteelPeak Wealth LLC purchased a new stake in Tempus AI, acquiring 5,709 shares valued at approximately $363,000 during the second quarter.
• Institutional investors, including Vanguard and ARK Investment Management, have significantly increased their holdings, now owning a combined total of millions of shares of Tempus AI.
• Tempus AI recently reported a quarterly revenue of $314.64 million, exceeding analyst estimates and showing an impressive year-over-year increase of 89.5%.

SteelPeak Wealth LLC bought a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,709 shares of the company's stock, valued at approximately $363,000.

A number of other large investors also recently modified their holdings of TEM. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 6,247.5% in the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock valued at $289,204,000 after purchasing an additional 5,900,668 shares in the last quarter. ARK Investment Management LLC lifted its holdings in shares of Tempus AI by 35.9% in the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock valued at $361,867,000 after purchasing an additional 1,981,755 shares in the last quarter. Nikko Asset Management Americas Inc. lifted its holdings in shares of Tempus AI by 31.5% in the first quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock valued at $205,401,000 after purchasing an additional 1,021,460 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 31.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock valued at $205,284,000 after purchasing an additional 1,016,384 shares in the last quarter. Finally, CloudAlpha Capital Management Limited Hong Kong bought a new position in shares of Tempus AI in the first quarter valued at approximately $34,119,000. Institutional investors own 24.22% of the company's stock.

Tempus AI Stock Performance

Shares of TEM opened at $103.25 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58. The stock has a 50 day moving average of $77.21 and a 200 day moving average of $64.16. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $103.42. The company has a market capitalization of $17.94 billion, a price-to-earnings ratio of -86.76 and a beta of 4.87.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. During the same period last year, the business posted ($6.86) earnings per share. The business's revenue for the quarter was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Insiders Place Their Bets

In other Tempus AI news, CAO Ryan M. Bartolucci sold 1,904 shares of the firm's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $142,133.60. Following the completion of the sale, the chief accounting officer directly owned 45,895 shares of the company's stock, valued at $3,426,061.75. This trade represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Eric P. Lefkofsky sold 332,500 shares of the firm's stock in a transaction on Thursday, September 25th. The stock was sold at an average price of $76.56, for a total value of $25,456,200.00. Following the completion of the sale, the chief executive officer directly owned 9,141,032 shares of the company's stock, valued at $699,837,409.92. This represents a 3.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 933,662 shares of company stock valued at $68,070,993. Company insiders own 26.27% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Guggenheim raised their target price on Tempus AI from $80.00 to $95.00 and gave the company a "buy" rating in a report on Friday, September 26th. BTIG Research increased their price target on Tempus AI from $75.00 to $85.00 and gave the company a "buy" rating in a research report on Wednesday, August 20th. Morgan Stanley increased their price target on Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a research report on Tuesday, August 12th. Bank of America increased their price target on Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a research report on Wednesday, June 25th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $70.00 price target on shares of Tempus AI in a research report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $71.83.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.